Phase 2 Clinical Efficacy and Safety Study of Sabizabulin (VERU-111) Monotherapy and Sacituzumab Govitecan-hziy/Sabizabulin Combination Therapy for the Treatment of Metastatic Triple Negative Breast Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 10 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sabizabulin (Primary) ; Sacituzumab govitecan (Primary)
Indications Advanced breast cancer; Triple negative breast cancer
Focus Registrational; Therapeutic Use
Acronyms VERU-111
Sponsors Veru Healthcare

Most Recent Events

24 Jan 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
19 Oct 2021 Planned initiation date changed from 30 Sep 2021 to 30 Dec 2021.
25 Jun 2021 According to a Veru media release, company plans to commence this study in Q3 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight